FDA approves BI’s Gilotrif for lung cancer

The US Food and Drug Administration has approved Boehringer Ingelheim’s Gilotrif (afatinib) for patients with metastatic non-small cell lung cancer whose tumours express specific epidermal growth factor receptor (EGFR) gene mutations.